Pascal Guntern
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Pascal Guntern has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Eggel
Department for BioMedical Research University of Bern Bern Switzerland
3 shared publications Daniel Brigger
Universitat Bern Department for BioMedical Research
3 shared publications- Pascal Gasser
Mabylon AG Zürich Switzerland
2 shared publications Alexander Eggel
Universitat Bern Department for BioMedical Research
1 shared publicationAlicia Shiu
Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, USA
1 shared publication- Carsten Riether
Tumor Immunology, Department for BioMedical Research (DBMR), University of Bern, Bern, Switzerland
1 shared publication
Latest Publications
- Open Access
- 3 July 2025
- Published by Wiley
Age-related increase in anaphylaxis severity is associated with enhanced sensitivity to allergic mediators
- 3 July 2025
- Published by Wiley
Open AccessAge-related increase in anaphylaxis severity is associated with enhanced sensitivity to allergic mediators
- 6 July 2020
- Published by Springer Nature in Nature Metabolism
- Vol. 2 (8) , 688-702
Eosinophils regulate adipose tissue inflammation and sustain physical and immunological fitness in old age
Adipose tissue eosinophils (ATEs) are important in the control of obesity-associated inflammation and metabolic disease. However, the way in which ageing impacts the regulatory role of ATEs remains unknown. Here, we show that ATEs undergo major age-related changes in distribution and function associated with impaired adipose tissue homeostasis and systemic low-grade inflammation in both humans and mice. We find that exposure to a young systemic environment partially restores ATE distribution in aged parabionts and reduces adipose tissue inflammation. Approaches to restore ATE distribution using adoptive transfer of eosinophils from young mice into aged recipients proved sufficient to dampen age-related local and systemic low-grade inflammation. Importantly, restoration of a youthful systemic milieu by means of eosinophil transfers resulted in systemic rejuvenation of the aged host, manifesting in improved physical and immune fitness that was partially mediated by eosinophil-derived IL-4. Together, these findings support a critical function of adipose tissue as a source of pro-ageing factors and uncover a new role of eosinophils in promoting healthy ageing by sustaining adipose tissue homeostasis.
- 6 July 2020
- Published by Springer Nature in Nature Metabolism
- Vol. 2 (8) , 688-702
Eosinophils regulate adipose tissue inflammation and sustain physical and immunological fitness in old age
Adipose tissue eosinophils (ATEs) are important in the control of obesity-associated inflammation and metabolic disease. However, the way in which ageing impacts the regulatory role of ATEs remains unknown. Here, we show that ATEs undergo major age-related changes in distribution and function associated with impaired adipose tissue homeostasis and systemic low-grade inflammation in both humans and mice. We find that exposure to a young systemic environment partially restores ATE distribution in aged parabionts and reduces adipose tissue inflammation. Approaches to restore ATE distribution using adoptive transfer of eosinophils from young mice into aged recipients proved sufficient to dampen age-related local and systemic low-grade inflammation. Importantly, restoration of a youthful systemic milieu by means of eosinophil transfers resulted in systemic rejuvenation of the aged host, manifesting in improved physical and immune fitness that was partially mediated by eosinophil-derived IL-4. Together, these findings support a critical function of adipose tissue as a source of pro-ageing factors and uncover a new role of eosinophils in promoting healthy ageing by sustaining adipose tissue homeostasis.
- Open Access
Past, present, and future of anti‐IgE biologics
About 20 years after the identification of immunoglobulin E (IgE) and its key role in allergic hypersensitivity reactions against normally harmless substances, scientists have started inventing strategies to block its pathophysiological activity in 1986. The initial concept of specific IgE targeting through the use of anti‐IgE antibodies has gained a lot of momentum and within a few years independent research groups have reported successful generation of first murine monoclonal anti‐IgE antibodies. Subsequent generation of optimized chimeric and humanized versions of these antibodies has paved the way for the development of therapeutic anti‐IgE biologicals as we know them today. With omalizumab, there is currently still only one therapeutic anti‐IgE antibody approved for the treatment of allergic conditions. Since its application is limited to the treatment of moderate‐to‐severe persistent asthma and chronic spontaneous urticaria, major efforts have been undertaken to develop alternative anti‐IgE biologicals that could potentially be used in a broader spectrum of allergic diseases. Several new drug candidates have been generated and are currently assessed in pre‐clinical studies or clinical trials. In this review, we highlight the molecular properties of past and present anti‐IgE biologicals and suggest concepts that might improve treatment efficacy of future drug candidates.
Open AccessPast, present, and future of anti‐IgE biologics
About 20 years after the identification of immunoglobulin E (IgE) and its key role in allergic hypersensitivity reactions against normally harmless substances, scientists have started inventing strategies to block its pathophysiological activity in 1986. The initial concept of specific IgE targeting through the use of anti‐IgE antibodies has gained a lot of momentum and within a few years independent research groups have reported successful generation of first murine monoclonal anti‐IgE antibodies. Subsequent generation of optimized chimeric and humanized versions of these antibodies has paved the way for the development of therapeutic anti‐IgE biologicals as we know them today. With omalizumab, there is currently still only one therapeutic anti‐IgE antibody approved for the treatment of allergic conditions. Since its application is limited to the treatment of moderate‐to‐severe persistent asthma and chronic spontaneous urticaria, major efforts have been undertaken to develop alternative anti‐IgE biologicals that could potentially be used in a broader spectrum of allergic diseases. Several new drug candidates have been generated and are currently assessed in pre‐clinical studies or clinical trials. In this review, we highlight the molecular properties of past and present anti‐IgE biologicals and suggest concepts that might improve treatment efficacy of future drug candidates.
- Top Cited PapersOpen Access
- 8 January 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-14
The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab
Targeting of immunoglobulin E (IgE) represents an interesting approach for the treatment of allergic disorders. A high-affinity monoclonal anti-IgE antibody, ligelizumab, has recently been developed to overcome some of the limitations associated with the clinical use of the therapeutic anti-IgE antibody, omalizumab. Here, we determine the molecular binding profile and functional modes-of-action of ligelizumab. We solve the crystal structure of ligelizumab bound to IgE, and report epitope differences between ligelizumab and omalizumab that contribute to their qualitatively distinct IgE-receptor inhibition profiles. While ligelizumab shows superior inhibition of IgE binding to FcεRI, basophil activation, IgE production by B cells and passive systemic anaphylaxis in an in vivo mouse model, ligelizumab is less potent in inhibiting IgE:CD23 interactions than omalizumab. Our data thus provide a structural and mechanistic foundation for understanding the efficient suppression of FcεRI-dependent allergic reactions by ligelizumab in vitro as well as in vivo.
- 8 January 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-14
Top Cited PapersOpen AccessThe mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab
Targeting of immunoglobulin E (IgE) represents an interesting approach for the treatment of allergic disorders. A high-affinity monoclonal anti-IgE antibody, ligelizumab, has recently been developed to overcome some of the limitations associated with the clinical use of the therapeutic anti-IgE antibody, omalizumab. Here, we determine the molecular binding profile and functional modes-of-action of ligelizumab. We solve the crystal structure of ligelizumab bound to IgE, and report epitope differences between ligelizumab and omalizumab that contribute to their qualitatively distinct IgE-receptor inhibition profiles. While ligelizumab shows superior inhibition of IgE binding to FcεRI, basophil activation, IgE production by B cells and passive systemic anaphylaxis in an in vivo mouse model, ligelizumab is less potent in inhibiting IgE:CD23 interactions than omalizumab. Our data thus provide a structural and mechanistic foundation for understanding the efficient suppression of FcεRI-dependent allergic reactions by ligelizumab in vitro as well as in vivo.